Impact of HMGB1 on Diastolic Dysfunction in Hypertensive Patients
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
All of the hypertensive patients in both diastolic dysfunction and control groups were either newly diagnosed or were aware of hypertension without using any pharmacotherapy.
-
Exclusion Criteria:
Individuals already under treatment for hypertension were not include.
-
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Differences of HMGB1 levels between hypertensive patients with and without diastolic dysfunction
Time Frame: on the day of admission
|
Blood samples of all individuals are collected on the day of admission and HMGB1 levels are tested.
Echocardiographic assessment is performed with echocardiography device by using 2.5-3.5 Mega Hertz(MHz) transducer in the lateral decubitis position.
|
on the day of admission
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Differences of HMGB1 levels between grades of diastolic dysfunction
Time Frame: on the day of admission
|
Blood samples of all individuals are collected on the day of admission and HMGB1 levels are tested.
Echocardiographic assessment is performed with echocardiography device by using 2.5-3.5 Mega Hertz(MHz) transducer in the lateral decubitis position.
|
on the day of admission
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2017032901
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammation
-
NCT01488500CompletedSystemic Inflammation | Respiratory Inflammation
-
NCT00673907CompletedSystemic Inflammation | Airway Inflammation
-
NCT00455377CompletedAirway Inflammation | Peripheral Blood Inflammation Markers | Cement Dust Exposure
-
NCT07395921Not yet recruitingInflammaging | Antioxidant Status, Inflammation | Inflammation Biomarkers | Antioxidant Capabilities | Cardiometabolic Health Indicators
-
NCT06467968Recruiting
-
NCT05886855Not yet recruiting
-
NCT04546295Completed
-
NCT05017428CompletedPostprandial Inflammation
-
NCT02675543CompletedVitreous Inflammation
-
NCT07506993RecruitingPeriodontal Inflammation